Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul;1(3):224-7.
doi: 10.18632/oncotarget.129.

Is miR-29 an oncogene or tumor suppressor in CLL?

Yuri Pekarsky  1 , Carlo M Croce
Affiliations

Is miR-29 an oncogene or tumor suppressor in CLL?

Yuri Pekarsky et al. Oncotarget. 2010 Jul.

Abstract

B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in the Western world. CLL occurs in two forms, aggressive and indolent. Aggressive CLL is characterized by high ZAP-70 expression and unmutated IgH V(H); indolent CLL shows low ZAP-70 expression and mutated IgH V(H). We recently found that miR-29 is up-regulated in indolent human B-CLL, compared to aggressive B-CLL and normal CD19(+) B-cells. To determine the role of miR-29 in CLL, we generated transgenic mice over-expressing miR-29 in mouse B-cells. Recently we reported that miR-29 transgenic mice develop indolent CLL phenotype. Interestingly, our previous findings suggest that miR-29 targets expression of TCL1, a critical oncogene in aggressive CLL, indicating that miR-29 might function as a tumor suppressor in CLL. Here we discuss these results and provide additional insights into function of miR-29 in CLL.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Role of miR-29 in CLL.
See this image and copyright information in PMC

Similar articles

  • Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
    Santanam U, Zanesi N, Efanov A, Costinean S, Palamarchuk A, Hagan JP, Volinia S, Alder H, Rassenti L, Kipps T, Croce CM, Pekarsky Y. Santanam U, et al. Proc Natl Acad Sci U S A. 2010 Jul 6;107(27):12210-5. doi: 10.1073/pnas.1007186107. Epub 2010 Jun 21. Proc Natl Acad Sci U S A. 2010. PMID: 20566844 Free PMC article.
  • Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181.
    Pekarsky Y, Santanam U, Cimmino A, Palamarchuk A, Efanov A, Maximov V, Volinia S, Alder H, Liu CG, Rassenti L, Calin GA, Hagan JP, Kipps T, Croce CM. Pekarsky Y, et al. Cancer Res. 2006 Dec 15;66(24):11590-3. doi: 10.1158/0008-5472.CAN-06-3613. Cancer Res. 2006. PMID: 17178851
  • TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.
    Balatti V, Rizzotto L, Miller C, Palamarchuk A, Fadda P, Pandolfo R, Rassenti LZ, Hertlein E, Ruppert AS, Lozanski A, Lozanski G, Kipps TJ, Byrd JC, Croce CM, Pekarsky Y. Balatti V, et al. Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2169-74. doi: 10.1073/pnas.1500010112. Epub 2015 Feb 2. Proc Natl Acad Sci U S A. 2015. PMID: 25646413 Free PMC article.
  • Novel insights in molecular mechanisms of CLL.
    Zanesi N, Balatti V, Bottoni A, Croce CM, Pekarsky Y. Zanesi N, et al. Curr Pharm Des. 2012;18(23):3363-72. doi: 10.2174/138161212801227104. Curr Pharm Des. 2012. PMID: 22591386 Review.
  • miR deregulation in CLL.
    Balatti V, Pekarky Y, Rizzotto L, Croce CM. Balatti V, et al. Adv Exp Med Biol. 2013;792:309-25. doi: 10.1007/978-1-4614-8051-8_14. Adv Exp Med Biol. 2013. PMID: 24014303 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sgambati M, Linet M, Devesa S. Chronic Lymphocytic Leukemia, Epidemiological, Familial, and Genetic Aspects. In: Cheson B, editor. Chronic Lymphocytic Leukemias. Second Edition. Marcel Dekker, Inc; New York: 2001. pp. 33–62. Revised and Expanded.
    1. Bullrich F, Croce C. Molecular Biology of Chronic Lymphocytic Leukemia. In: Cheson B, editor. Chronic Lymphocytic Leukemias. Second Edition. Marcel Dekker, Inc; New York: 2001. pp. 9–32. Revised and Expanded.
    1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116:281–297. - PubMed
    1. Fabbri M, Ivan M, Cimmino A, Negrini M, Calin GA. Regulatory mechanisms of microRNAs involvement in cancer. Expert Opin Biol Ther. 2007;7:1009–1019. - PubMed
    1. Zhang H, Chen Y. New insight into the role of miRNAs in leukemia. Sci China C Life Sci. 2009;52:224–231. - PubMed

MeSH terms